{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4358","statisticalMethod":"Stratified Log Rank"},{"ciLowerLimit":"0.77","ciNumSides":"TWO_SIDED","ciPctValue":"95.71","ciUpperLimit":"1.12","estimateComment":"E-Ld/Ld. Calculated using Cox proportional hazards modeling","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.93"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.18","upperLimit":"36.80","value":"31.38"},{"groupId":"OG001","lowerLimit":"23.49","upperLimit":"34.30","value":"29.47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"374"}],"units":"Participants"}],"description":"PFS is defined as the time from randomization to the date of the first documented tumor progression (as determined by the Independent Review Committee (IRC)) or death due to any cause.\n\nThe IRC conducted a blinded, independent review of the tumor assessments based on the European Group for Blood and Bone Marrow Transplant (EBMT) criteria.\n\nCensoring rules applied:\n\n* Participants receiving subsequent systemic anti-myeloma therapy prior to documented progression were censored at the date of the last adequate tumor assessment prior to new therapy.\n* Participants who had an event (progression or death) \\> 10 weeks after their last tumor assessment were censored at their last adequate tumor assessment prior to the event.\n* Participants without progression or death (and not receiving subsequent therapy prior to progression) were censored at their last adequate tumor assessment.\n* Participants without any post-baseline tumor assessments were censored on the date of randomization","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receiving a combination of Elotuzumab (E) Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG000","title":"E-Ld Cohort"},{"description":"Participants receiving a combination of Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG001","title":"Ld Cohort"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)","title":"Progression-Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Months"}